newsroom /

Milan, Italy Sep. 29, 2023


Milan, Italy (September 29th, 2023) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to 78TH ANNUAL MEETING OF THE ASSH. The event will be held October 5 - 7, 2023 in Toronto – ON. Gabriella Francavilla, Global Marketing Manager, will be attending the congress with the aim to strengthen current relationships and establish new ones with physicians and strategic partners, in order to implement KLISBio’s Early Adopters Engagement Plan by starting preliminary conversation with PNR surgeons.

Among the best innovators in Peripheral Nerve Repair and Regenerative Medicine participating in 2023 ASSH Annual Meeting, KLISBio is committed to contributing to the advancement of PNR space with SILKBridge Nerve Guide. SILKBridge is an off-the-shelf, absorbable medical device made of Bombyx mori silk fibroin and is intended for the surgical repair of peripheral nerve discontinuities to support axonal regeneration across the defect.

“For several years, we have been working with a world-renowned panel of KOLs in hand surgery both in US and EU with the view to make SILKBridge Nerve Guide a competitive solution for peripheral nerve repair, designing preclinical and clinical activities and gathering all data needed to raise interest among the PNR surgeons. We are now ready to expand our relations and create a panel of Early Adopters with whom we would like to activate further dialogs, before implementing an already-designed clinical and go-to-market strategy.” said Gabriella Francavilla, Global Marketing Manager.

The patented 3D architecture of SILKBridge shows two working mechanisms in one device. SILKBridge multilayered structure has an optimized balance between biomechanical and biological properties, complementing the high strength of native silk fibers and the enhanced biomimicry of electrospun silk. The inner and outer electrospun layers are specifically designed to promote cell adhesion and resorb faster. The morphological properties of electrospun fibers mimic the nanoscale structure of the extracellular matrix. The intermediate textile layer is made of a textile component and is designed to confer high mechanical performance and resistance to the device and to resorb at a slower rate. SILKBridge Nerve Guide is not yet FDA cleared.

KLISBio holds patents in Silk regenerated Fibroin + Native Silk Fibroin Pairing, Silk-based Composites and Core-Shell Silk Nanofibers. The Company is powered by a group of world leaders in MedTech including Grecchi, CEO; Antonio Alessandrino, Chief Technology Officer and Giuliano Freddi, Chief Scientific Officer, Rodrigo Bianchi, serving as Chairman of the Board with more than three decades of experience in global healthcare. In addition to its strong leadership team, KLISBio works with physicians, engineers, researchers, chemists and biologists worldwide who represent excellence in the biomedical space.

About KLISBio:

KLISBio is a clinical-stage regenerative medicine company focused on developing innovative technology platforms entirely based on natural silk fibroin. The company, headquatered in Milan, Italy, currently has several assets under development, such as vascular graft, bone graft substitutes and rotator cuff repair.